The trusted source for
healthcare information and
Eli Lilly and Co. of Indianapolis has launched two new products important to diabetes management.
Recombinant glucagon for use in severe hypoglycemic events has replaced the company’s animal-source glucagon product and was expected to be available in pharmacies in March.
The Humulin 70/30 (70% human insulin isophane suspension, 30% human insulin), Humulin N, and Humalog injections are intended to simplify insulin delivery.
The pre-filled disposable pens hold 300 units of insulin. No refrigeration is necessary after the first use. The pocket-sized pen has a magnified dosage window to dispense precise quantities of insulin. It’s designed to improve glycemic control in patients with irregular schedules.